anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Midfoot arthritis is a common condition leading to disabling chronic foot pain that affects activities of daily living. The causes can be primary osteoarthritis (OA), inflammatory or post-traumatic. We are looking at OA of the lesser (second and/or third) tarsometatarasal joints (TMTJ). Orthotics, customised shoes or steroid injections are options to treat this condition nonoperatively. If these measures fail, arthrodesis of the arthritic joints represents the standard procedure to surgical treatment. Generally, the results of this procedure are at a satisfactory level for the patients, nevertheless, there is a relevant amount of patients with residual pain, lack of a normal foot appearance, and the need for unplanned surgery or use of orthotics postoperatively. Furthermore, patients undergoing an arthrodesis of the lesser TMTJ usually have to stay in hospital for 4-7 days. Postoperatively, patients are only allowed to partially weightbear for at least 6 weeks and need a cast for six weeks as well. During that time thrombosis prophylaxis is administered for about 6 weeks.

The conventional distal minimal-invasive metatarsal osteotomy (DMMO) is an accepted technique for metatarsal osteotomies. Recently, Schneider et al. presented results of a modification of the conventional DMMO, the reverse DMMO to treat OA of the lesser TMTJ, thus representing an alternative treatment to arthrodesis. The procedure has many benefits. It allows outpatient care, an immobilisation in a cast is not necessary. Instead, patients have to wear a flat postoperative shoe for 2-3 weeks and are allowed to fully weightbear from day one after surgery. Therefore, thrombosis prophylaxis is not necessary unless there are specific risk factors.

However, while the arthrodesis directly addresses the arthritic joints, the R-DMMO alters the ground reaction force of the metatarsal head leading to less stress at the level of the TMTJ, but the arthritic joint itself is not approached. Still, the results presented by Schneider et al. are promising. Since there was no group to compare the treatment with, the small sample size, and a retrospective design, we would like to prospectively compare these two surgical procedures directly in order to find out whether or not the R-DMMO can be recommended as a standard procedure for OA of the lesser TMTJ at a much more convenient level for patients regarding the whole perioperative protocol. No vulnerable population is included. The scientific value is remarkable since this would be the first study to examine this matter and we are able to provide a high level of evidence due to the prospective-randomised and comparative design of the study. All legal requirements will be fulfilled and the ethical standards are guaranteed.

Both procedures have been described and the technique of the DMMO itself is not new, but its modification (R-DMMO) represents a new approach for this condition. Both procedures are reliable and safe, which is why the risk category of the study is A according to ClinO, Art. 61.
The most potent risk factor for the development of bipolar disorder (BP) is a first-degree family member with the illness. Thus, offspring of parents with BP are a particularly high-risk group and typically experience early illness onset, severe course, and high rates of comorbid psychiatric disorders. It is well-established that poor sleep regulation is associated with the onset of depressive and manic episodes among individuals with a biological vulnerability to mood disorder. Furthermore, evidence supports sleep disturbance in at-risk youth who have not yet developed threshold mood disorders. The proposed study aims to address this core disturbance that we argue puts at-risk youth at even greater risk for development of BP-sleep and social rhythm disruption. Since adolescence is a period characterized by significant alterations in sleep/wake patterns and social routines, this period may prove optimal for assessment and treatment of sleep and psychiatric symptoms in those at-risk. The investigators adapted and piloted Interpersonal and Social Rhythm Therapy (IPSRT), an empirically-supported treatment for adults with BP that helps patients stabilize sleep/wake cycles and daily routines, for at-risk adolescents. Preliminary data indicate this approach holds promise for youth at-risk for the development of BP. The investigators also identified intervention for the heterogeneous conditions antecedent to BP as a second path to preventing or delaying BP onset in at-risk youth. The purpose of the proposed study is thus to further develop and examine IPSRT for the adolescent (age 12-18) offspring of parents with BP. The study involves conduct of a small controlled trial (n=50) comparing Brief IPSRT + Data-Informed Referral versus Data-Informed Referral alone to gather preliminary data on feasibility, acceptability and proximal outcomes associated with the intervention. All participants receive a thorough assessment of psychopathology and sleep disturbance (via objective and subjective methods) at baseline, followed by a single feedback session reviewing the findings. As clinically indicated, youth will be offered Data-Informed Referral for any psychiatric symptoms/disorders identified during the intake assessment. Youth will then be randomized to receive either Brief IPSRT or no Brief IPSRT; randomization will be stratified on sleep disturbance and psychopathology. Outcomes will be assessed at 4 time points over 6 months in all participants. Data will be used to inform the design and conduct of a future controlled trial. The proposed approach is in direct accord with strategies outlined in the National Institute of Mental Health (NIMH) Strategic Plan in which the development and testing of innovative interventions to reduce risk and positively alter trajectories of mental illness are informed by research findings regarding robust and malleable risk factors and core features of disease. Research in this area is of great public health importance, as it has the potential to prevent, delay, or ameliorate the progression of this chronic and devastating illness in those at highest risk.
FIELD: biotechnology, veterinary virology. SUBSTANCE: method deals with virus-containing extraembryonic liquid of duck embryos infected with SDEY-76, B- 8/78 strain. Inactivation of viral raw material is conducted with 1.8.3.6-diendomethylene-1.3.6.8-tetroazatricyclodecane at the rate of 1.5-2.0 g preparation/1000 sm 3 . Hemagglutinin titer of inactivated viral raw material is taken up to 1: 4096 ratio due to adding a sterile buffered physiological solution or analogous viral raw material at a high hemagglutinin titer. Viral raw material is supplemented with an adjuvant based upon mineral oil. The mixture obtained is passed through a colloid mill. The vaccine obtained is used to vaccinate 110- d-aged chickens by injecting per 0.5 sm 3  vaccine intramuscularly. When observing the chickens during the period of 21 d no clinical signs of mentioned disease are seen and no alterations are detected at the sites of vaccine injections. Titers of antibodies in chickens' blood serum on the 21st d after vaccination correspond to 1:64 - 1: 312 that indicates immune response providing 100% protection. EFFECT: higher efficiency.
<P>PROBLEM TO BE SOLVED: To provide a neurite extension promoting agent capable of promoting the regeneration of the central nerve.  <P>SOLUTION: The neurite extension promoting agent contains, as an active component, a polypeptide having neurite extension promoting activity such as a polypeptide at least containing CEP-68 protein or its center region. A polypeptide having a neurite extension promoting activity was first found by the invention. The polypeptide has the activity to promote the extension of the neurite of the central nerve. Accordingly, the neurite extension promoting agent is useful for the regeneration of the central nerve.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The total duration of the study was 32 weeks and the study consisted of Periods A, B, and A+. Patients entered the study in Period A and were treated open-label with one of six commercially available antidepressant treatments (ADTs) for 8 weeks. Patients who met the blinded response criteria at the Week 6 Visit, were deemed early responders and were withdrawn from the study. At Week 8, patients with inadequate response to placebo + ADT, as per the randomisation criteria, entered Period B and were randomised to received double-blind brexpiprazole + ADT or placebo + ADT for 24 weeks. Non-randomised patients continued in Period A+ and received placebo + ADT until the end of the study. The primary objective was to compare the efficacy and safety of brexpiprazole with placebo. This comparison occurred Period B; therefore, the focus is Period B.
This will be a prospective pre-post mixed methods hybrid type 2 effectiveness-implementation study. The study will take place at BWH and at Vanderbilt University Medical Center (VUMC). The direct subjects will be the inpatient pharmacists (4 at each site) who round with general medicine teams. Patients will be indirect subjects as pharmacists provide medication recommendations regarding these patients to the clinicians on each team with or without the Synapse software. We estimate this number of patients to be 3 new admitted patients per day per team x 56 days x 8 teams = 1344 patients (672 at MGB sites). Patients can be any patients admitted to these general medicine service teams at BWH and VUMC. The pharmacists are trained hospital pharmacists who round with general medicine service teams and approve inpatient medication orders. There are no local site restrictions. VUMC will cede IRB approval to the MGB IRB.
Anti-BCMA binding moieties are provided herein in several embodiments. These anti-BCMA binding moieties can be used for BCMA-directed Chimeric Antigen Receptor (CAR). Also disclosed herein are immune cell-based compositions comprising an anti-BCMA binding moiety and a BCMA directed CAR. In several embodiments, the immune cell-based composition further targets additional tumor markers and/or additional epitopes of BCMA. In several embodiments, the BCMA directed CAR is expressed in natural killer cells. In several embodiments, a combination of BCMA-CAR expressing NK cells is administered in combination with CAR-expressing NK cells and/or CAR-expressing T cells, e.g., for additional cancer markers and/or additional epitopes of BCMA. Also provided herein are methods and uses of the chimeric antigen receptor in immunotherapy.
<P>PROBLEM TO BE SOLVED: To solve problems of a conventional carbohydrate microneedle wherein the needle part is broken in a part around a weak bonded part between the needle part and a base plate part and the needle part cannot stick in the skin when the needle part is inserted into the skin because the needle part and the base plate part are made of different materials and the bond between the needle part and the base plate part is weak, and wherein the practical utility is extremely impaired because a medicament, etc. is mounted on the upper surface of the needle part only, and as a result, the size of the medicament etc. is limited and the dose of the medicament to the skin is limited, or the like.  <P>SOLUTION: The carbohydrate microneedle is composed of one or a plurality of carbohydrate microneedles disposed and integrated in the shape of a comb on a side face of a microneedle attaching margin. The attaching margin is welded to a side end or biting part on the upper surface of the base plate made of a different material. As a result, the strength in the vicinity of the root of the needle part is high, so that the effect of easy sticking in the skin, and the effect of mounting a larger quantity of medicaments on the upper surface of the needle part and the upper surface of the attaching margin can be provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
A method for manufacturing a resin-impregnated endless belt structure having a texturized outer surface requires the use of a support structure, either a cylindrical mandrel or a pair of carrying rolls, having a texturized surface. An endless, permeable base structure is placed about the support structure, which is adapted to place the base structure under tension in a longitudinal direction. A polymeric resin material is dispensed onto the outside of the base structure on the support structure. The polymeric resin material totally impregnates the base structure and passes therethrough to coat the texturized surface of the support structure. A layer of polymeric aresin material is also built up on the outside of the base structure. The polymeric resi material is then cured, and may be ground to provide the layer of polymeric resin material with a smooth, uniform surface, and the belt structure thus obtained is removed from the support structure. The belt structure is finally turned inside out, placing an impression of the texturized surface of the support structure on the outside of the belt structure, that texturized surface having a plurality of indentations for the temporary storage of water pressed from a fibrous web in a press nip.
Participants in this arm will will receive all treatments assigned to arm 3, plus social gamification feedback, where each week participants are told if they've reach their weekly handheld phone use while driving reduction goal, and receive or lose points based on whether or not they met their goal. Based on their points participants can either move up or down a level. Each week the participants will also be sent a leader board of their ranking within their group.
MicroRNAs (miRNAs) are a group of non‑coding RNAs that exert master regulatory functions in post‑-transcriptional gene expression. Accumulating evidence shows that miRNAs can either promote or suppress tumorigenesis by regulating different target genes or pathways and may be involved in the occurrence of carcinoma. miR‑409‑3p is dysregulated in a variety of malignant cancers. It plays a fundamental role in numerous cellular biological processes, such as cell proliferation, apoptosis, migration, invasion, autophagy, angiogenesis and glycolysis. In addition, studies have shown that miR‑409‑3p is expected to become a non‑invasive biomarker. Identifying the molecular mechanisms underlying miR‑409‑3p‑mediated tumor progression will help investigate miR‑409‑3p‑based targeted therapy for human cancers. The present review comprehensively summarized the recently published literature on miR‑409‑3p, with a focus on the regulation and function of miR‑409‑3p in various types of cancer, and discussed the clinical implications of miR‑409‑3p, providing new insight for the diagnosis and treatment of cancers.
BACKGROUND: 16p11.2 proximal deletion and duplication syndromes (Break points 4-5) (593KB, Chr16; 29.6-30.2mb - HG38) are observed to have highly varied phenotypes, with a known propensity for lifelong psychiatric problems. This study aimed to contribute to a research gap by qualitatively exploring the challenges families with 16p11.2 deletion and duplication face by answering three research questions: (1) What are parents' perceptions of the ongoing support needs of families with children who have 16p11.2 living in the UK?; (2) What are their experiences in trying to access support?; (3) In these regards, do the experiences of parents of children with duplication converge or vary from those of parents of children with 16p11.2 deletion?
METHODS: 33 parents with children (aged 7-17 years) with 16p11.2 deletion or duplication participated in structured interviews, including the Autism Diagnostic Interview- Revised (ADI-R). Their answers to the ADI-R question 'what are your current concerns' were transcribed and subsequently analysed using Braun and Clarke's six step reflexive thematic analysis framework.
RESULTS: Three themes were identified: (1) Child is Behind Peers (subthemes: developmentally; academically; socially; emotionally); (2) Metabolism and Eating Patterns and; (3) Support (subthemes: insufficient support available; parent has to fight to access support; COVID-19 was a barrier to accessing support; 16p11.2 diagnosis can be a barrier to support, child is well-supported).
CONCLUSIONS: Parents of children with either 16p11.2 deletion or duplication shared similar experiences. However, metabolism concerns were specific to parents of children with 16p11.2 deletion. The theme Child is Behind Peers echoed concerns raised in previous Neurodevelopmental Copy Number Variant research. However, there were some key subthemes relating to research question (2) which were specific to this study. This included parents' descriptions of diagnostic overshadowing and the impact of a lack of eponymous name and scant awareness of 16p11.2.
The purpose of this study is to examine if a biologically active commercially available amnion chorion membrane (ACM) is as effective as the commercially available inert dense polytetrafluoroethylene membrane (D-PTFE) in preserving jaw bone dimensions and whether it provides the added benefit of reducing post-operative discomfort after dental surgery. The hypotheses for the study is that the use of ACM in preservation of bone dimensions in extraction socket will result in greater remaining horizontal and vertical ridge dimension, and reduced postoperative discomfort when compared with D-PTFE in sites where extraction socket will not be closed by advancing the gums. Subjects in need of single rooted teeth extraction on both left and right side of the same jaw will be recruited. Pre-surgical clinical and radiological measurements will be made using dental calipers, stents and reduced cone beam computed tomography (CBCT) three dimensional scans. Involved teeth will be extracted with minimal trauma. Freeze dried bone allograft (bone from human donors) will be used in all extraction sockets. ACM will be used in the one extraction socket and D-PTFE in the other extraction socket without advancing the gums to cover the socket. A Visual Analog Score (VAS), pain scale questionnaire will be given to record the postoperative discomfort and patient will be seen for routine post-operative monitoring as well as research measurements. At 3-months recall postoperatively, clinical measurements and radiographic measurements will be recorded as before. Wound fluid will also be collected at all visits. The sites will be reentered and trephine core (bone sample) will be collected for histomorphometric as well as microtomographic assessment. Statistical analysis will be performed to test the significance using a mixed-model analysis of variance (ANOVA).
The invention describes the expression of a human immunodeficiency virus (HIV) type 1 provirus (F12-HIV) cloned from a nonproducer, chronically-infected CD4 down-regulated Hut-78 cell clone (F12) which does not lead to the formation of viral particles and, upon transfection in HeLa CD4+ cells, confers resistance to HIV superinfection without affecting CD4 receptor exposure. A Moloney murine leukemia virus-based retroviral vector containing an F12-HIV genome lacking the 3' long terminal repeat (LTR) and part of the nef gene, expressed under the control of its 5' LTR, was constructed to facilitate the transfer of the anti-HIV properties of F12-HIV into human cells. The F12-HIV genome was inserted in an orientation opposite to that of the murine leukemia virus transcriptional unit and was designated the N2/F12-HIV nef- antisense vector. Lymphoblastoid CEMss cells, as well as human peripheral blood lymphocytes, were successfully transduced by the recombinant retrovirus. CEMss clones expressing the F12-HIV nef- antisense vector were resistant to HIV superinfection even at the highest multiplicity of infection tested (105 50% tissue culture infective doses per 106 cells). Nonproducer, interfering HIV proviruses transduced into retroviral vectors may provide an alternative strategy for the protection of CD4+ human primary cells from HIV infection.
SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
The data of all patients who applied to Samsun Training and Research Hospital for 12 months in 2022 and diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of use of new generation oral anticoagulants in patients with rebleeding was determined, and data such as rebleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it.
Improved agents and methods of treatment for a variety of diseases in animals and humans are disclosed. The agent is an innovative composition comprising a bacterial-based culture. In particular, the innovative compositions disclosed herein are active molecules produced by gram-negative bacterial strains belonging to the genus Brevundimonas. Eating the innovative composition in liquid or dry feed yields many health benefits and has proven to be effective in controlling disease. Bacteria of the disclosed compositions selectively modulate Toll-like receptors (TLRs) to control coccidiosis and the like. Specific effects include, but are not limited to, improving intestinal health, accelerating or enhancing immune responses using natural immunomodulators, and promoting animal growth.
Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
FIELD: medicine, toxicology. SUBSTANCE: treatment involves the combined use of activated carbon sorbent, polysorb and stimulating agents of vegetable origin showing adaptogenic effect. Carbolong is used as an activated carbon sorbent. Phytoinfusions were used also that show sorption capability. EFFECT: enhanced effectiveness of treatment, decreased by-side effects. 3 cl, 2 tbl
The invention relates to a deep sea elastase gene as well as a preparation method and an application thereof, belonging to the field of biotechnology. The invention relates to a cryophilic bacterium CF6-2, a cryophilic elastase gene extracted from the cryophilic bacterium CF6-2 and deep sea elastase expressed and translated by the gene. The cryophilic elastase derives from a deep sea low-temperature high-salinity environment. Compared with other kinds of elastase, the cryophilic elastase has higher elastin degradation efficiency in sea water at 0-30 DEG C and can exert functions at normal temperature. The cryophilic elastase is extremely unstable at the temperature above 40 DEG C and is inactivated at middle temperature, so that the safety of the cryophilic elastase is ensured. The cryophilic elastase has cracking activity on various gram-positive bacteria, not only can be applied to the fields of medical treatment, daily chemical industry and the like, but also has great application potential in the fields of marine biomedicine, aquatic product processing and the like.
AMELUZ, in conjunction with lesion preparation, is only to be administered by a health care provider.

AMELUZ is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Treat single lesions or an entire field affected by multiple lesions with AMELUZ, in combination with red light photodynamic therapy (PDT). PDT requires administration of both AMELUZ and BF-RhodoLED or RhodoLED XL light.

Refer to BF-RhodoLED or RhodoLED XL user manual for detailed lamp safety and operating instructions. Adhere to all safety instructions for both patient and medical personnel while conducting the PDT.